Last reviewed · How we verify
NCT05106465
A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage
trial testing Konectom platform in Multiple Sclerosis (MS) in 200 participants. Completed in 3 April 2024.
3 April 2024
Quick facts
| Lead sponsor | Biogen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 December 2021 |
| Primary completion | 3 April 2024 |
| Estimated completion | 3 April 2024 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Konectom platform
Conditions studied
- Multiple Sclerosis (MS) — all drugs for Multiple Sclerosis (MS) →
Sponsor
Biogen — full company profile →
Who can join
18 and older, any sex, with Multiple Sclerosis (MS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to explore association patterns between digital outcome assessments from Konectom and MRI measures of brain tissue damage.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05106465
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis (MS)
Currently open trials in the same condition.
- NCT07526493 — Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media · Phase 1 · recruiting
- NCT06869278 — A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases · Phase 1 · recruiting
- NCT06053749 — An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimest · active not recruiting
- NCT06270641 — Increasing Physical Activity for Adults With Multiple Sclerosis (MS) · NA · recruiting
- NCT06157086 — Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France · active not recruiting
Other Biogen trials
Trials by the same sponsor.
- NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
- NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
- NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
- NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
- NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05106465 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biogen
- Last refreshed: 17 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05106465.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing